ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Prime Medicine Inc

Prime Medicine Inc (PRME)

2.75
-0.08
(-2.83%)
Closed January 30 3:00PM
2.80
0.05
(1.82%)
After Hours: 5:00PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
2.80
Bid
2.75
Ask
2.84
Volume
621,602
2.70 Day's Range 2.88
2.56 52 Week Range 9.77
Market Cap
Previous Close
2.83
Open
2.81
Last Trade
7
@
2.83
Last Trade Time
Financial Volume
US$ 1,738,683
VWAP
2.7971
Average Volume (3m)
1,126,129
Shares Outstanding
131,160,842
Dividend Yield
-
PE Ratio
-1.82
Earnings Per Share (EPS)
-1.51
Revenue
-
Net Profit
-198.13M

About Prime Medicine Inc

Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome a... Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
-
Prime Medicine Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker PRME. The last closing price for Prime Medicine was US$2.83. Over the last year, Prime Medicine shares have traded in a share price range of US$ 2.56 to US$ 9.77.

Prime Medicine currently has 131,160,842 shares outstanding. The market capitalization of Prime Medicine is US$371.19 million. Prime Medicine has a price to earnings ratio (PE ratio) of -1.82.

PRME Latest News

Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic...

Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates

-- Presented initial in vivo data for universal liver-targeted LNP and Wilsonโ€™s Disease program at ESGCT; initiated IND-enabling activities for Wilsonโ€™s Disease program in 4Q 2024 and remains on...

Prime Medicine to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.12-4.10958904112.923.342.7559490403.07630174CS
4-0.12-4.10958904112.923.592.638423303.03586899CS
12-1.29-31.54034229834.094.712.5611261293.20644435CS
26-2.82-50.17793594315.625.942.5612121553.64493376CS
52-3.85-57.89473684216.659.772.5610178564.79149822CS
156-16.17-85.239852398518.9721.73012.566539327.11072855CS
260-16.17-85.239852398518.9721.73012.566539327.11072855CS

PRME - Frequently Asked Questions (FAQ)

What is the current Prime Medicine share price?
The current share price of Prime Medicine is US$ 2.80
How many Prime Medicine shares are in issue?
Prime Medicine has 131,160,842 shares in issue
What is the market cap of Prime Medicine?
The market capitalisation of Prime Medicine is USD 371.19M
What is the 1 year trading range for Prime Medicine share price?
Prime Medicine has traded in the range of US$ 2.56 to US$ 9.77 during the past year
What is the PE ratio of Prime Medicine?
The price to earnings ratio of Prime Medicine is -1.82
What is the reporting currency for Prime Medicine?
Prime Medicine reports financial results in USD
What is the latest annual profit for Prime Medicine?
The latest annual profit of Prime Medicine is USD -198.13M
What is the registered address of Prime Medicine?
The registered address for Prime Medicine is CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
What is the Prime Medicine website address?
The website address for Prime Medicine is www.primemedicine.com
Which industry sector does Prime Medicine operate in?
Prime Medicine operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
DGNXDiginex Ltd
US$ 49.18
(228.09%)
3.34M
SLXNSilexion Therapeutics Corporation
US$ 3.1301
(131.86%)
330.45M
KRKR36Kr Holdings Inc
US$ 9.10
(114.12%)
23.61M
SPGCSacks Parente Golf Inc
US$ 0.6001
(57.92%)
52.17M
XFORX4 Pharmaceuticals Inc
US$ 0.7542
(56.54%)
42.5M
ZKINZK International Group Co Ltd
US$ 0.4813
(-41.21%)
3.1M
MGOLMGO Global Inc
US$ 0.1019
(-38.73%)
70.52M
BACKIMAC Holdings Inc
US$ 0.7869
(-35.50%)
2.37M
EYENEyenovia Inc
US$ 0.03695
(-35.18%)
25.31M
HAOHaoxi Health Technology Ltd
US$ 2.52
(-31.89%)
484.94k
NVDANVIDIA Corporation
US$ 123.70
(-4.10%)
466.94M
SLXNSilexion Therapeutics Corporation
US$ 3.1301
(131.86%)
330.45M
OCEAOcean Biomedical Inc
US$ 0.249929
(-24.26%)
186.52M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.428
(-6.98%)
148.12M
RIMEAlgorhythm Holdings Inc
US$ 0.0259
(-16.18%)
138.96M

PRME Discussion

View Posts
Monksdream Monksdream 1 month ago
PRME, under $

๐Ÿ‘๏ธ0
PonkenPlonken PonkenPlonken 2 months ago
Super super undervalued..
Recent PSTX - Roche deal should have made this run? Atleast given it also recently partnered with BMS... makes zero sense.
Is a clear validation CRISPR genome editing is hot in cancer cell therapy.
Waiting for a sign....
๐Ÿ‘๏ธ0
Monksdream Monksdream 3 months ago
PRME under $5
๐Ÿ‘๏ธ0
Monksdream Monksdream 4 months ago
PRME new 52 week low
๐Ÿ‘๏ธ0
Invest-in-America Invest-in-America 4 months ago
PRME: Glad I grabbed a chunk of THIS ONE!!!!
๐Ÿ‘๏ธ0
PonkenPlonken PonkenPlonken 4 months ago
"Under the terms of the agreement, Prime Medicine will receive a $55 million upfront payment and a $55 million equity investment from Bristol Myers Squibb. Prime Medicine is also eligible to receive more than $3.5 billion in milestones,..."

"On the Effective Date, the Company entered into the Purchase Agreement with BMS, pursuant to which the Company agreed to issue and sell, and BMS agreed to purchase, in an unregistered offering (the โ€œOfferingโ€), 11,006,163 shares [...] for an aggregate purchase price of $55.0 million..."
๐Ÿ‘๏ธ0
Monksdream Monksdream 5 months ago
PRME new 52=week low
๐Ÿ‘๏ธ0
wiwineguy wiwineguy 5 months ago
K. I'm in!
๐Ÿ‘๏ธ0
Monksdream Monksdream 5 months ago
DAKT
๐Ÿ‘๏ธ0
wiwineguy wiwineguy 5 months ago
You are amazing Monk. Any recommendations
๐Ÿ‘๏ธ0
Monksdream Monksdream 5 months ago
PRME under $5
๐Ÿ‘๏ธ0
Monksdream Monksdream 6 months ago
PRME new 52 week low
๐Ÿ‘๏ธ0
Monksdream Monksdream 6 months ago
PRME under $6
๐Ÿ‘๏ธ0
Monksdream Monksdream 7 months ago
PRME under $10:
๐Ÿ‘๏ธ0
Monksdream Monksdream 8 months ago
Great post
Friday Cathie Wood bought more shares for her flagship Ark Fund (ARKK)
I think she has been buying on the decline
She isnโ€™t particularly interested in how well or how lousy the management controls costs itโ€™s the potential she believes exists
There are about a dozen, if not more, listed gene editing companies
Not all will make it before they run out of money and have to raise more operating capital
Notice the $2 to $4 bounces on the way to lower lows
๐Ÿ‘๏ธ0
Monksdream Monksdream 8 months ago
PRME under $10
๐Ÿ‘๏ธ0
jondoeuk jondoeuk 8 months ago
PRME vs Tome vs Tessera vs NTLA vs CRSP vs...!

They fact this article needs to be written could mean a legal battle is coming https://www.nature.com/articles/s41587-024-02208-0
๐Ÿ‘๏ธ0
NY1972 NY1972 9 months ago
This $500M company burns $200M a year. These PhDs have been spoiled by Wall St. when money was cheap. Who wants to be their sugar daddy?
๐Ÿ‘๏ธ0
jondoeuk jondoeuk 9 months ago
I'm sure in the (near) future they will (functionally) cure (rare) diseases, but not before they dilute a whole bunch more.
๐Ÿ‘๏ธ0
jondoeuk jondoeuk 11 months ago
The CEO has been contently telling investors how easy it would be to bring in funding through partnerships and how difficult capital markets are. Yet they did a secondary. He needs to go. Also, I don't think their IP is gatekeeping others.
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock